Relationship of the phenotype of peripheral blood lymphocytes and signs of osteopenia in patients with chronic lymphocytic leukemia
- Authors: Osikov M.V.1,2, Korobkin E.A.1,2, Fedosov A.A.3, Dimov G.P.1
-
Affiliations:
- South Ural State Medical University
- Chelyabinsk Regional Clinical Hospital
- P. Lumumba Peoples’ Friendship University of Russia
- Issue: Vol 27, No 2 (2024)
- Pages: 375-382
- Section: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/1028-7221/article/view/263702
- DOI: https://doi.org/10.46235/1028-7221-16583-ROT
- ID: 263702
Cite item
Full Text
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries, characterized by the development of a number of complications, including osteoporosis, which is a prerequisite for studying its predictors. The purpose of the work is to investigate the relationship between immunophenotyping indicators of blood lymphocytes and osteodensitometry indicators in CLL. The study was conducted on 48 male patients with CLL aged 50-70 years with an average disease duration of 12 months and 14 apparently healthy men of the corresponding age (group 1). In the blood, CD5+, CD19+, CD20+, CD22+, CD23+, CD43+, and CD200+ lymphocytes were differentiated in the blood using flow cytometry. The international FRAX questionnaire was used to assess the probability of fracture. Osteodensitometry assessed bone mineral density (BMD), T-score (standard deviation, SD), Z-score (SD) in the lumbar spine (LS), proximal femoral neck (FNA), proximal femoral bone (PFB). Patients with CLL were included in group 2 (n = 34) with BMD within normal limits (T- and Z-score > – 1.0 SD) or group 3 (n = 14) with signs of osteopenia (OP) (T- and Z-score from – 1.0 SD up to – 2.5 SD). In patients with CLL in group 3, compared with patients with CLL in group 2, there is a significant increase in the number of lymphocytes in the blood expressing markers CD5+, CD19+, CD20+, CD22+, CD23+, CD43+, and CD200+. In patients with CLL in group 3, signs of AP in the SPBC increase with the increase in lymphocytes with the CD5+, CD19+, CD20+, CD22+, CD23+, CD43+, CD200+ phenotype in the blood. Signs of AP in the PBC increase with the increase in lymphocytes with the CD5+, CD19+, CD20+, CD23+, CD43+ phenotype in the blood. The strongest connections were found between the number of lymphocytes in the blood with the markers CD5+, CD19+, CD23+, CD43+ and the T-score, Z-score, and BMD in the FNA. The data obtained are a prerequisite for further study of the interaction between the clone of tumor lymphocytes in CLL and cells involved in bone tissue remodeling to identify the mechanism of development of OP, osteoporosis and the risk of bone fractures, and changes in the quantitative composition of the lymphocyte phenotype in the blood can be considered as potential laboratory predictors of a decrease in BMD.
Full Text
##article.viewOnOriginalSite##About the authors
M. V. Osikov
South Ural State Medical University; Chelyabinsk Regional Clinical Hospital
Author for correspondence.
Email: prof.osikov@yandex.ru
PhD, MD (Medicine), Head, Pathophysiology Department; Head, Scientific Department
Russian Federation, Chelyabinsk; ChelyabinskE. A. Korobkin
South Ural State Medical University; Chelyabinsk Regional Clinical Hospital
Email: prof.osikov@yandex.ru
Assistant, Pathophysiology Department; Hematologist
Russian Federation, Chelyabinsk; ChelyabinskA. A. Fedosov
P. Lumumba Peoples’ Friendship University of Russia
Email: prof.osikov@yandex.ru
PhD (Medicine), Associate Professor, Department of Histology, Cytology and Embryology
Russian Federation, MoscowG. P. Dimov
South Ural State Medical University
Email: prof.osikov@yandex.ru
PhD (Medicine), Research Associate, Head, department of Collection, Procurement and Storage of Hematopoietic Cells and Bone Marrow
Russian Federation, ChelyabinskReferences
- Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., Дзеранова Л.К., Драпкина О.М., Древаль А.В., Дубовицкая Т.А., Дудинская Е.Н., Ершова О.Б., Загородний Н.В., Илюхина О.Б., Канис Дж.А., Крюкова И.В., Лесняк О.М., Мамедова Е.О., Марченкова Л.А., Мельниченко Г.А., Никанкина Л.В., Никитинская О.А., Петряйкин А.В., Пигарова Е.А., Родионова С.С., Рожинская Л.Я., Скрипникова И.А., Тарбаева Н.В., Ткачева О.Н., Торопцова Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Остеопороз и остеопатии, 2021. Т. 24, № 2. С. 4-47. [Belaya Zh.E., Belova K.Yu., Biryukova E.V., Dedov I.I., Dzeranova L.K., Drapkina O.M., Dreval A.V., Dubovitskaya T.A., Dudinskaya E.N., Ershova O.B., Zagorodniy N.V., Ilyukhina O.B., Kanis J.A., Kryukova I.V., Lesnyak O M., Mamedova E.O., Marchenkova L.A., Melnichenko G.A., Nikankina L.V., Nikitinskaya O.A., Petryaykin A.V., Pigarova E.A., Rodionova S.S.., Rozhinskaya L.Ya., Skripnikova I.A., Tarbaeva N.V., Tkacheva O.N., Toroptsova N.V., Farba L.Ya., Tsoriev T.T., Chernova T.O., Yureneva S.V., Yakushevskaya O.V.Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases, 2021, Vol. 24, no. 2, pp. 4-47. (In Russ.)]
- Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с. [Malignant neoplasms in Russia in 2020 (morbidity and mortality). Ed. Kaprin A.D., Starinskiy V.V., Shahzadova A.O.] Moscow: P. HerzenMoscow Research Oncology Institute, National Medical Research Radiological Centre of the Ministry Of Health of the Russian Federation, 2021. 252 p.
- Никитин Е.А., Бялик Т.Е., Зарицкий А.Ю., Исебер Л., Капланов К.Д., Лопаткина Т.Н., Луговская С.А., Мухортова О.В., Османов Е.А., Поддубная И.В., Самойлова О.С., Стадник Е.А., Фалалеева Н.А., Байков В.В., Ковригина А.М., Невольских А.А., Иванов С.А., Хайлова Ж.В., Геворкян Т.Г. Хронический лимфоцитарный лейкоз/лимфома из малых лимфоцитов. Клинические рекомендации // Современная онкология, 2020. № 22 (3). С. 24-44. [Nikitin E.A., Bialik T.E., Zaritsky A.Y., Iseber L., Kaplanov K.D., Lopatkina T.N., Lugovskaya S.A., Mukhortova O.V., Osmanov E.A., Poddubnaya I.V., Samoilova O.S., Stadnik E.A., Falaleeva N.A., Baykov V.V., Kovrigina A.M., Nevolskikh A.A., Ivanov S.A., Khailova Zh.V., Gevorkyan T.G. Chronic lymphocytic leukemia/small lymphocyte lymphoma. Clinical recommendations. Sovremennaya onkologiya = Modern Oncology, 2020, no. 22 (3), pp. 24-44. (In Russ.)]
- Alankus B., Ecker V., Vahl N., Braun M., Weichert W., Macher-Göppinger S., Gehring T., Neumayer T., Zenz T., Buchner M., Ruland J. Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. J. Exp. Med., 2021, Vol. 218, no. 2, e20200517. doi: 10.1084/jem.20200517.
- Alisson-Silva F., Mantuano N.R., Lopes A.L., Vasconcelos-Dos-Santos A., Vale A.M., Costa M.M., Cannon J.L., Oliveira A.C., Todeschini A.R. CD43 sialoglycoprotein modulates cardiac inflammation and murine susceptibility to Trypanosoma cruzi infection. Sci. Rep., 2019, Vol. 9, 8628. doi: 10.1038/s41598-019-45138-7.
- Brander D.M., Oeffinger K.C., Greiner M.A., Dinan M.A. Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL). J. Clin. Oncol., 2020, Vol. 38, no. 15 suppl., e24050. doi: 10.1200/JCO.2020.38.15_suppl.e24050.
- Čamernik K., Mihelič A., Mihalič R., Haring G., Herman S., Marolt Presen D., Janež A., Trebše R., Marc J., Zupan J. Comprehensive analysis of skeletal muscle- and bone-derived mesenchymal stem/stromal cells in patients with osteoarthritis and femoral neck fracture. Stem Cell Res. Ther., 2020, Vol. 11, no. 1, 146. doi: 10.1186/s13287-020-01657-z.
- El-Gazzar A., Högler W. Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. Int. J. Mol. Sci., 2021, Vol. 22, no. 2, 625. doi: 10.3390/ijms22020625.
- Giannoni P., Marini C., Cutrona G., Todoerti K., Neri A., Ibatici A., Sambuceti G., Pigozzi S., Mora M., Ferrarini M., Fais F., de Totero D. A high percentage of CD16+ monocytes correlates with the extent of bone erosion in chronic lymphocytic leukemia patients: the impact of leukemic b cells in monocyte differentiation and osteoclast maturation. Cancers (Basel), 2022, Vol. 14, no. 23, 5979. doi: 10.3390/cancers14235979.
- Jiang Z., Jin L., Jiang C., Yan Z., Cao Y. IL-1 contributes to the secretion of sclerostin by osteocytes and targeting sclerostin promotes spinal fusion at early stages. J. Orthop. Surg. Res., 2023, Vol. 18, no. 1, 162. doi: 10.1186/s13018-023-03657-0.
- Li Y., Tong X., Huang L., Li L., Wang C., He C., Liu S., Wang Z., Xiao M, Mao X, Zhang D. A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Med., 2021, Vol. 10, no. 13, pp. 4387-4396.
- Petty L., Stephens D., Sharma A. ODP090 fragility fractures and osteoporosis screening in patients with chronic lymphocytic leukemia. J. Endocr. Soc., 2022, Vol. 6, Iss. suppl. 1, pp. A162-A163.
- Rotbain E.C., Gordon M.J., Vainer N., Frederiksen H., Hjalgrim H., Danilov A.V., Niemann C.U. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Adv., 2022, Vol. 6, no. 8, pp. 2701-2706.
- Valderrábano R.J., Wu J.Y. Bone and blood interactions in human health and disease. Bone, 2019, Vol. 119, pp. 65-70.
- Yao Z., Getting S.J., Locke I.C. Regulation of TNF-induced osteoclast differentiation. Cells, 2021, Vol. 11, no. 1, 132. doi: 10.3390/cells11010132.
Supplementary files
